Professor Mark Boyd
Chair of Medicine
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Boyd is an internationally recognised infectious disease expert. He has led project teams in HIV research in Thailand, as well as at the Kirby Institute for infection and immunity at the University of New South Wales. He has published results from randomised trials that changed international guidelines for the treatment of adults living with HIV worldwide.
Since moving to the University of Adelaide based at the Lyell McEwin Hospital in Adelaide's north, Boyd has shifted his attention to the health needs of people living in the substantially disadvantaged communities that the hospital serves. Transformative improvements in health and wellbeing in these communities will not come from better access to new pharmaceutical magic bullets, but from interventions that decrease the extreme social stress under which many people live - financial instability, housing insecurity, food scarcity, etc. The challenge is to reconfigure the health system to not only provide the standard pharmaceutical and technical solutions, but also work to help solve the social stressors. This guides our research and our passion for meaningful change in healthcare delivery.
Research
Population and individual health are profoundly influenced by social determinants of health. Evidence clearly demonstrates that health and disease are strongly linked with social advantage,. There is a ‘social gradient of health' favouring the socially advantaged over the disadvantaged. Despite this, the health system focuses on the biomedical aspects of acute and chronic health conditions and generally ignores the ‘upstream’ determinants that underpin illness. The Northern Health Project (NHP) explores the potential to broaden health care delivery toward a more comprehensive approach that addresses both biomedical (‘downstream’) and social (‘upstream’) risks. This makes particular sense at the Lyell McEwin Hospital (LMH), which serves one of the most disadvantaged urban populations in Australia. We developed a qualitatively validated questionnaire ('Social Needs Screening Tool' [SDST]) to identify patients with unmet social needs. The tool is in active use in research at LMH in exploring how to manage patient social risk(s) by referral to relevant community services for resolution/assistance.
The NHP is elaborating research projects in the following areas:
- Identifying the social risks of defined patients and patient populations (e.g. people living with cancer, people living with atrial fibrillation)
- Developing and testing models of care that reduce social risk by connecting patients with community-based social care resources.
- Including social risk in algorithms to predict early, unexpected readmission to hospital
- Exploring associations between social risk and specific diseases
- Systematically canvassing opinion amongst the multiple stakeholders engaged in the delivery of healthcare (including the community).
Projects
I have supervised 4 Honours students over the past 4 years. All were awarded First Class Honours.
Project 1
Title: Exploring the upstream and down stream risks for Atrial Fibrillation
Description: In collaboration with A/Prof Rajiv Mahajan, an internationally recognised expert in cardiac arrhythmia, we will explore associations between atrial fibrillation (AF; the most common cardiac arrhythmia), social risks, conventional risks and types of AF. We will do this in the AF cohort that A/Prof Mahajan leads (co-supervisor).
Project available for: Honours
Location: UoA precinct, Lyell McEwin Hospital
Research Project start: Semester 2, 2023
Project 2
Title: Weighting the Social Needs Screening Tool
Description: The SDST collects data that is highly granular and thereby offers the opportunity to explore the associations between specific types of disadvantage (or clusters of disadvantage) and specific disease states far more accurately than conventional means (e.g. by using postcode data). We will explore this research question in a collaboration with A/Prof Mahajan.
Projects available for: Honours
Location: UoA precinct, Lyell McEwin Hospital
Research Project start: Semester 2, 2023
Project 3
Title: Stakeholder opinion and attitudes and engagement in screening for unmet social needs in hospital.
Description: Screening and addressing social needs in the hospital would involve an adaptation of conventional practice. Community engagement will be key to successful adaptation of models of care. We will conduct Focus Group sessions of community representatives and advocates to understand community opinions and ideas as well as engagement in systems change.
Project available for: Honours
Location: UoA precinct, Lyell McEwin Hospital
Research Project start: Semester 2, 2023
Please contact me by e-mail if any of these (or similar ideas) appeal. We are interested in your ideas and happy to discuss how these could be translated into research projects in the domain of integrating conventional medical care with social care to create comprehensive healthcare.
-
Appointments
Date Position Institution name 2015 - 2016 Visiting Medical Officer Murrumbidgee Health District 2015 - 2016 Visiting Medical Officer Albury Wodonga Health District 2013 - 2016 Associate Professor University of New South Wales 2007 - 2012 Clinical Project Leader St Vincent's Hospital 2004 - 2007 Senior Consultant in Infectious Diseases and Microbiology Flinders Medical Centre 2000 - 2004 Clinical Project Leader HIV Netherlands Australia Thailand Research Collaboration -
Awards and Achievements
Date Type Title Institution Name Country Amount 2014 Award The Frank Fenner Award for Advanced Research in Infectious Diseases Australasian Society for Infectious Diseases (ASID) Inc. - - 2014 Award Outstanding Reviewer for 2013 - - - 1986 Award The Alfred Houston Senior Prize in Philosophy University of Tasmania - - -
Education
Date Institution name Country Title 2006 Flinders University Australia (MHID) - Master of Health and International Development 2001 - 2006 University of New South Wales Australia MD - Doctor of Medicine 1997 University of Alabama (USA) and Universidad Peruana Cayetano-Heredia (Perú) Peru and United States DCTM&H - Dip. In Clinical. Trop. Med. and Hygiene 1987 - 1992 Flinders University Australia BM, BS Medicine, Surgery 1983 - 1986 University of Tasmania Australia BA Philosophy - English Literature -
Certifications
Date Title Institution name Country 2013 Graduate Certificate in University Learning and Teaching University of New South Wales Australia 2011 Certificate for Ethics Training for Human Research Ethics Committee members Monash University Australia 1995 Fellowship Royal Australasian College of Physicians Australia -
Research Interests
-
Journals
Year Citation 2023 Edwards, S., Puljević, C., Dean, J. A., Gilks, C., Boyd, M. A., Baker, P., . . . Gartner, C. E. (2023). Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV. AIDS and Behavior, 27(2), 618-627.
2023 Poirier, B. F., Ribeiro Santiago, P. H., Kapellas, K., Jamieson, L., Neadley, K. E., & Boyd, M. (2023). Development of Social Determinants of Health Screening Tool (SDoHST): qualitative validation with stakeholders and patients in South Australia. Current Medical Research and Opinion, 39(1), 131-140.
Scopus2 Europe PMC22023 Heron, J. E., McManus, H., Vickers, T., Ryan, K., Wright, E., Carter, A., . . . West, M. (2023). Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study. PLoS ONE, 18(2 February), e0280339.
2023 Stretton, B., Kovoor, J., Bacchi, S., Booth, A., Gluck, S., Vanlint, A., . . . Boyd, M. (2023). Impact of perioperative direct oral anticoagulant assays: a multicenter cohort study. Hospital Practice, 51(3), 155-162.
2023 Karran, E. L., Cashin, A. G., Barker, T., Boyd, M. A., Chiarotto, A., Dewidar, O., . . . Identifying Social Factors that Stratify Health Opportunities and Outcomes (ISSHOOs) Collaborative Core Research Group. (2023). The 'what' and 'how' of screening for social needs in healthcare settings: a scoping review. PeerJ, 11, e15263-1-e15263-19.
Scopus12023 Stretton, B., Tran, V., Kovoor, J. G., Gupta, A. K., Bacchi, S., Maddern, G. J., & Boyd, M. (2023). Phone home: The translational benefits of space medicine for rural and remote perioperative medicine on Earth.. The Australian journal of rural health, 31(4), 782-784.
2023 Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., . . . Horowtiz, M. (2023). Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Internal Medicine Journal, 53(8), 1311-1320.
2023 Stretton, B., Kovoor, J., Gupta, A., Hains, L., Bacchi, S., Wong, B., . . . Maddern, G. (2023). Get out what you put in: optimising electronic medical record data. ANZ Journal of Surgery, 93(9), 2056-2058.
2023 Taylor, S. L., Papanicolas, L. E., Flynn, E., Boyd, M. A., Wesselingh, S. L., & Rogers, G. B. (2023). Preventing empirical antibiotic treatment failure in migrant populations: screening by infection risk, not ethnic background. International Journal of Infectious Diseases, 134, 168-171.
2023 Mascaro, S., Wu, Y., Woodberry, O., Nyberg, E. P., Pearson, R., Ramsay, J. A., . . . Richards, T. (2023). Modeling COVID-19 disease processes by remote elicitation of causal Bayesian networks from medical experts. BMC Medical Research Methodology, 23(1), 1-21.
Scopus12023 Stretton, B., Eranki, A., Kovoor, J., Bacchi, S., Gupta, A., Maddern, G., & Boyd, M. (2023). Too Sour to be True? Tart Cherries (Prunus cerasus) and Sleep: a Systematic Review and Meta-analysis. Current Sleep Medicine Reports, 9(3), 225-233.
2022 Freeman, T., Fisher, M., Foley, K., Boyd, M. A., Ward, P. R., McMichael, G., . . . Dekker, G. (2022). Barriers to digital health services among people living in areas of socioeconomic disadvantage: Research from hospital diabetes and antenatal clinics.. Health Promot J Austr, 33(3), 751-757.
Scopus22022 Lake, K. J., Boyd, M. A., Smithers, L., Howard, N. J., & Dawson, A. P. (2022). Exploring the readiness of senior doctors and nurses to assess and address patients' social needs in the hospital setting.. BMC health services research, 22(1), 12 pages.
Scopus1 WoS1 Europe PMC12022 Walls, A., Boyd, M., McMichael, G., & Smithers, L. G. (2022). Can social risks in early life predict children’s health and academic outcomes? An analysis of the Longitudinal Study of Australian Children. SSM - Population Health, 17, 1-8.
Scopus1 WoS12022 Lake, K. J., Boyd, M. A., Smithers, L., Howard, N. J., & Dawson, A. P. (2022). Correction to: Exploring the readiness of senior doctors and nurses to assess and address patients' social needs in the hospital setting.. BMC health services research, 22(1), 359.
2022 Traeger, M. W., Guy, R., Asselin, J., Patel, P., Carter, A., Wright, E. J., . . . West, M. (2022). Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data. The Lancet Infectious Diseases, 22(8), 1231-1241.
Scopus4 Europe PMC12022 Harney, B. L., Sacks-Davis, R., Van Santen, D. K., Traeger, M., Wilkinson, A. L., Asselin, J., . . . West, M. (2022). The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019. Clinical Infectious Diseases, 74(10), 1804-1811.
Scopus8 Europe PMC42022 Lathlean, T., Kieu, D., Franke, K. B., O'Callaghan, N., Boyd, M. A., & Mahajan, R. (2022). Impact of health literacy and its interventions on health outcomes in those with atrial fibrillation: A systematic review protocol. BMJ Open, 12(12), 5 pages.
2021 Jiamsakul, A., Boyd, M., Choi, J. Y., Edmiston, N., Kumarasamy, N., Hutchinson, J., . . . Ditangco, R. (2021). Trends in Follow-Up Visits Among People Living With HIV: Results From the TREAT Asia and Australian HIV Observational Databases. Journal of acquired immune deficiency syndromes (1999), 88(1), 70-78.
2021 Nyein, P. P., Aung, E., Aung, N. M., Kyi, M. M., Boyd, M., Lin, K. S., & Hanson, J. (2021). The impact of gender and the social determinants of health on the clinical course of people living with HIV in Myanmar: an observational study. AIDS Research and Therapy, 18(1), 1-7.
Scopus2 Europe PMC22021 Ashokan, A., Hanson, J., Aung, N. M., Kyi, M. M., Taylor, S. L., Choo, J. M., . . . Rogers, G. B. (2021). Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income setting. Antimicrobial Resistance and Infection Control, 10(1), 56-1.
Scopus1 WoS12021 Rattanakosit, T., Franke, K., Munawar, D. A., Page, A. J., Boyd, M. A., Lau, D. H., & Mahajan, R. (2021). Role of Indices Incorporating Power, Force and Time in AF Ablation: A Systematic Review of Literature. Heart, Lung and Circulation, 30(9), 10 pages.
Scopus5 WoS3 Europe PMC22021 Neadley, K. E., McMichael, G., Freeman, T., Browne-Yung, K., Baum, F., Pretorius, E., . . . Boyd, M. A. (2021). Capturing the social determinants of health at the individual level: a pilot study.. Public health research & practice, 31(2), 1-7.
Scopus5 Europe PMC22021 Mak, G., Zaunders, J. J., Bailey, M., Seddiki, N., Rogers, G., Leong, L., . . . Danta, M. (2021). Preservation of gastrointestinal mucosal barrier function and microbiome in patients with controlled HIV infection. Frontiers in Immunology, 12, 688886-1-688886-15.
Scopus6 WoS6 Europe PMC22021 Lau, A., Kong, F. Y. S., Fairley, C. K., Templeton, D. J., Amin, J., Phillips, S., . . . Hocking, J. S. (2021). Azithromycin or doxycycline for asymptomatic rectal chlamydia trachomatis. New England Journal of Medicine, 384(25), 2418-2427.
Scopus28 WoS26 Europe PMC132021 Mwasakifwa, G. E., Amin, J., Kelleher, A., & Boyd, M. A. (2021). Inflammatory biomarker and soft tissue changes among patients commencing second-line ART after first-line virological failure. AIDS (London, England), 35(14), 2289-2298.
Scopus1 WoS1 Europe PMC12021 Patel, P. G., Keen, P., McManus, H., Duck, T., Callander, D., Selvey, C., . . . Clifton, B. (2021). Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men. HIV Medicine, 22(7), 605-616.
Scopus5 Europe PMC42021 Di Giallonardo, F., Pinto, A. N., Keen, P., Shaik, A., Carrera, A., Salem, H., . . . Mackie, B. (2021). Subtype-specific differences in transmission cluster dynamics of HIV-1 B and CRF01_AE in New South Wales, Australia. Journal of the International AIDS Society, 24(1), e25655-1-e25655-10.
Scopus5 Europe PMC22020 Yang, F., Janamnuaysook, R., Boyd, M. A., Phanuphak, N., & Tucker, J. D. (2020). Key populations and power: people-centred social innovation in Asian HIV services.. The lancet. HIV, 7(1), 69-74.
Scopus22 WoS22 Europe PMC142020 Ramachandran, J., Kaambwa, B., Muller, K., Haridy, J., Tse, E., Tilley, E., . . . Wigg, A. J. (2020). Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience. European Journal of Gastroenterology and Hepatology, 32(10), 1381-1389.
Scopus2 WoS2 Europe PMC12020 Dickinson, L., Gurjar, R., Stöhr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Moyano, B. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 75(3), 628-639.
Scopus7 Europe PMC52020 Vannakit, R., Andreeva, V., Mills, S., Cassell, M., Jones, M., Murphy, E., . . . Phanuphak, N. (2020). Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations. The Lancet HIV, 7(5), e366-e372.
Scopus17 WoS14 Europe PMC62020 Lau, A., Kong, F. Y. S., Fairley, C. K., Templeton, D. J., Amin, J., Boyd, M. A., . . . Hocking, J. S. (2020). Factors associated with early resumption of condomless anal sex among men who have sex with men after rectal chlamydia treatment. Sexually Transmitted Diseases, 47(6), 389-394.
Scopus3 WoS4 Europe PMC12020 Mwasakifwa, G. E., Amin, J., White, C. P., Center, J. R., Kelleher, A., & Boyd, M. A. (2020). Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.. HIV Medicine, 21(8), 492-504.
Scopus1 WoS12020 Thomson, S., Doan, T., Liu, D., Schubert, K. O., Toh, J., Boyd, M. A., & Galletly, C. (2020). Supporting the vulnerable: developing a strategic community mental health response to the COVID-19 pandemic. Australasian Psychiatry, 28(5), 492-499.
Scopus13 WoS13 Europe PMC92020 Denholm, J., Davis, J., Paterson, D., Roberts, J., Morpeth, S., Snelling, T., . . . Morpeth, S. (2020). The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), 646.
Scopus11 Europe PMC92020 Vannakit, R., Andreeva, V., Mills, S., Cassell, M., Jones, M., Murphy, E., . . . Phanuphak, N. (2020). HIV programmes in countries within the Asia-Pacific region – Authors' reply. The Lancet HIV, 7(8), e530-e531.
2020 Chakraborty, A., Pearson, O., Schwartzkopff, K. M., O'rourke, I., Ranasinghe, I., Mann Mah, P., . . . Wittert, G. (2020). The effectiveness of in-hospital interventions on reducing hospital length of stay and readmission of patients with Type 2 Diabetes Mellitus: a systematic review. Diabetes research and clinical practice, 174, 12 pages.
Scopus4 WoS3 Europe PMC22020 Khaw, C., Zablotska-Manos, I., & Boyd, M. A. (2020). Men who have Sex with Men and Chemsex: A Clinic-Based Cross-sectional Study in South Australia. Sexuality Research and Social Policy, 18(4), 1014-1022.
Scopus3 WoS32019 Bell, S., Mena, G., Dean, J., Watts, P., Howard, C., Boyd, M., . . . Gartner, C. (2019). Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 31(4), 436-442.
Scopus4 WoS4 Europe PMC22019 Melaku, Y. A., Gill, T. K., Appleton, S. L., Hill, C., Boyd, M. A., & Adams, R. J. (2019). Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: An 18-year follow-up of the North West Adelaide Health Study. BMJ Open, 9(8), e030079.
Scopus3 WoS3 Europe PMC22019 Boyd, M. A., Boffito, M., Castagna, A., & Estrada, V. (2019). Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Medicine, 20(S1), 3-11.
Scopus50 WoS44 Europe PMC292019 McManus, H., Callander, D., Donovan, B., Russell, D. B., O'Connor, C. C., Davies, S. C., . . . Guy, R. J. (2019). Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015. Medical Journal of Australia, 210(6), 269-275.
Scopus7 WoS5 Europe PMC22018 Wright, E., Grulich, A., Roy, K., Boyd, M., Cornelisse, V., Russell, D., . . . Zablotska, I. (2018). Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.. Journal of virus eradication, 4(2), 143-159.
Europe PMC32018 Giles, M. L., Gartner, C., & Boyd, M. A. (2018). Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?. AIDS Research and Therapy, 15(1), 5 pages.
Scopus25 WoS23 Europe PMC202018 Stockdale, A. J., Saunders, M. J., Boyd, M. A., Bonnett, L. J., Johnston, V., Wandeler, G., . . . Geretti, A. M. (2018). Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of Human Immunodeficiency Virus Type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clinical Infectious Diseases, 66(12), 1846-1857.
Scopus49 WoS46 Europe PMC302018 Boyd, M. A., & Cooper, D. A. (2018). Combination ART: are two drugs as good as three?. The Lancet, 391(10123), 817-819.
Scopus2 WoS2 Europe PMC22018 Mwasakifwa, G., Moore, C., Carey, D., Amin, J., Penteado, P., Losso, M., . . . Boyd, M. (2018). Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS, 32(3), 357-361.
Scopus3 WoS4 Europe PMC42018 Haridy, J., Wigg, A., Muller, K., Ramachandran, J., Tilley, E., Waddell, V., . . . Tse, E. (2018). Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. Journal of Viral Hepatitis, 25(11), 1287-1297.
Scopus28 WoS24 Europe PMC132018 Yao, A., Moore, C., Lim, P., Molina, J. -M., Madero, J., Kerr, S., . . . Boyd, M. (2018). Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. Antiviral therapy, 23(1), 21-32.
Scopus1 WoS1 Europe PMC12018 Boyd, M., Cooper, D., & Gilks, C. (2018). Towards a universal second-line fixed-dose combination ART. The Lancet HIV, 5(1), e3-e5.
Scopus4 WoS4 Europe PMC32017 Boyd, M., Mocroft, A., Ryom, L., d'Arminio Monforte, A., Sabin, C., El-Sadr, W., . . . Law, M. (2017). Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D:A:D observational study. PLoS Medicine, 14(11), e1002424-1-e1002424-14.
Scopus14 WoS12 Europe PMC102017 Bell, S., Mena, G., Dean, J., Boyd, M., Gilks, C., & Gartner, C. (2017). Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes. Drug and Alcohol Dependence, 177, 67-70.
Scopus8 WoS8 Europe PMC22017 Lau, A., Kong, F., Fairley, C., Donovan, B., Chen, M., Bradshaw, C., . . . Hocking, J. (2017). Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. BMC Infectious Diseases, 17(1), 35-1-35-9.
Scopus16 WoS16 Europe PMC92017 Aung, N., Hanson, J., Kyi, T., Htet, Z., Cooper, D., Boyd, M., . . . Saw, H. (2017). HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Research and Therapy, 14(1), 1-7.
Scopus13 WoS12 Europe PMC62017 Rhee, S., Varghese, V., Holmes, S., Van Zyl, G., Steegen, K., Boyd, M., . . . Shafer, R. (2017). Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. EBioMedicine, 18, 225-235.
Scopus24 WoS23 Europe PMC202017 Boyd, M. A. (2017). Body composition substudy of the SECOND-LINE study – Author's reply. The Lancet HIV, 4(6), e240.
2017 Bell, S., Dean, J., Gilks, C., Boyd, M. A., Fitzgerald, L., Mutch, A., . . . Gartner, C. E. (2017). Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health, 14(7), 12 pages.
Scopus10 WoS8 Europe PMC82017 Boyd, M. A., & Cooper, D. A. (2017). Long-acting injectable ART: next revolution in HIV?. The Lancet, 390(10101), 1468-1470.
Scopus13 WoS13 Europe PMC62017 Thit, S., Aung, N., Htet, Z., Boyd, M., Saw, H., Anstey, N., . . . Hanson, J. (2017). The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study. BMC Medicine, 15(1), 145-1-145-11.
Scopus21 WoS21 Europe PMC152017 Puhr, R., Petoumenos, K., Youds, D., Law, M. G., Templeton, D. J., Ellis, D., . . . Bargh, K. (2017). The impact of changes in HIV management guidelines on time to treatment initiation in Australia. HIV Medicine, 18(9), 701-703.
Scopus3 WoS3 Europe PMC32017 Boyd, M., Amin, J., Mallon, P., Kumarasamy, N., Lombaard, J., Wood, R., . . . Cooper, D. (2017). Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. The Lancet HIV, 4(1), e13-e20.
Scopus5 WoS5 Europe PMC42017 Petoumenos, K., Choi, J., Hoy, J., Kiertiburanakul, S., Ng, O., Boyd, M., . . . Law, M. (2017). CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antiviral Therapy, 22(8), 659-668.
Scopus14 WoS13 Europe PMC92017 Wright, E., Grulich, A., Roy, K., Boyd, M., Cornelisse, V., Russell, D., . . . Zablotska, I. (2017). Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. JOURNAL OF VIRUS ERADICATION, 3(3), 168-184.
WoS55 Europe PMC202016 Arts, E., & Boyd, M. (2016). Reviewer acknowledgement.. AIDS research and therapy, 13(1).
2016 Zaunders, J., Danta, M., Bailey, M., Mak, G., Marks, K., Seddiki, N., . . . Koelsch, K. (2016). CD4⁺ T follicular helper and IgA⁺ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals. Frontiers in Immunology, 7(OCT), 438.
Scopus12 WoS11 Europe PMC72016 Boyd, M., Cooper, D., Crock, E., Crooks, L., Giles, M., Grulich, A., . . . Yarwood, T. (2016). Sexual transmission of HIV and the law: An Australian medical consensus statement. Medical Journal of Australia, 205(9), 409-412.
Scopus8 WoS8 Europe PMC22016 Klassen, K., Kimlin, M., Fairley, C., Emery, S., Anderson, P., & Ebeling, P. (2016). Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporosis International, 27(5), 1737-1745.
Scopus9 WoS7 Europe PMC62016 Klassen, K., Kimlin, M., Fairley, C., Emery, S., Anderson, P., & Ebeling, P. (2016). Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporosis International, 27(5), 1737-1745.
Scopus9 WoS7 Europe PMC62016 Lam, E., Moore, C., Gotuzzo, E., Nwizu, C., Kamarulzaman, A., Chetchotisakd, P., . . . Boyd, M. (2016). Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study. AIDS Research and Human Retroviruses, 32(9), 841-850.
Scopus13 WoS13 Europe PMC92016 Achhra, A., Mwasakifwa, G., Amin, J., & Boyd, M. (2016). Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. The Lancet HIV, 3(8), e351-e360.
Scopus49 WoS45 Europe PMC282016 Alvarez, E., Belloso, W. H., Boyd, M. A., Inkaya, A. C., Hsieh, E., Kambugu, A., . . . Mallon, P. W. G. (2016). Which HIV patients should be screened for osteoporosis: An international perspective. Current Opinion in HIV and AIDS, 11(3), 268-276.
Scopus18 WoS15 Europe PMC132016 Boyd, M., & Cooper, D. (2016). Novel antiretroviral agents and universal access to HIV care. The Lancet HIV, 3(1), e2-e3.
Scopus1 WoS1 Europe PMC12016 Winston, A., Stöhr, W., Antinori, A., Arenas-Pinto, A., Llibre, J., Amieva, H., . . . Barea, C. (2016). Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 17(6), 471-478.
Scopus7 WoS5 Europe PMC42016 Lambert-Niclot, S., George, E., Pozniak, A., White, E., Schwimmer, C., Jessen, H., . . . Couffin-Cadiergues, S. (2016). Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 71(4), 1056-1062.
Scopus23 WoS24 Europe PMC172016 Boyd, M. A., & Cooper, D. A. (2016). Tenofovir alafenamide: safer, but questions remain. The Lancet HIV, 3(4), e148-e149.
Scopus2 WoS22015 Amin, J., Boyd, M. A., Kumarasamy, N., Moore, C. L., Losso, M. H., Nwizu, C. A., . . . Cooper, D. A. (2015). Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 )). PLoS ONE, 10(10), e0140623.
Scopus42015 Boyd, M. A., & Cooper, D. A. (2015). The LATTE study: A provocative brew. The Lancet Infectious Diseases, 15(10), 1116-1117.
Scopus1 WoS12015 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802.
Scopus95 WoS90 Europe PMC502015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS ONE, 10(2), e0118228.
Scopus20 WoS21 Europe PMC182015 Han, N., Wright, S., O'Connor, C., Hoy, J., Ponnampalavanar, S., Grotowski, M., . . . Pujari, S. (2015). HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD). HIV Medicine, 16(3), 152-160.
Scopus8 Europe PMC52015 McManus, H., Hoy, J. F., Woolley, I., Boyd, M. A., Kelly, M. D., Mulhall, B., . . . Law, M. G. (2015). Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 255.
2015 Boyd, M., Moore, C., Molina, J., Wood, R., Madero, J., Wolff, M., . . . Cooper, D. (2015). Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. The Lancet HIV, 2(2), 42-51.
Scopus64 WoS63 Europe PMC532015 Cummins, N., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J., . . . Badley, A. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine, 2(7), 706-712.
Scopus22 WoS19 Europe PMC142015 Boyd, M. A., Donovan, B., Prestage, G., Chen, M., Petoumenos, K., Gray, R., . . . Klausner, J. D. (2015). Is it time to rethink syphilis control?. Clinical Infectious Diseases, 60(2), 325-326.
Scopus5 WoS5 Europe PMC42015 Templeton, D., Wright, S., McManus, H., Lawrence, C., Russell, D., Law, M., . . . Boyd, M. (2015). Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 15(1), 1-8.
Scopus5 Europe PMC42015 Wright, S., Law, M., Cooper, D., Keen, P., McDonald, A., Middleton, M., . . . Sasisopin, A. (2015). Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 18(1), 19463.
Scopus10 WoS9 Europe PMC72015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 131-139.
Scopus6 WoS6 Europe PMC32015 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. G. (2015). Loss to follow-up in the Australian HIV Observational Database. ANTIVIRAL THERAPY, 20(7), 731-741.
WoS15 Europe PMC102015 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. G. (2015). Loss to follow-up in the Australian HIV Observational Database. ANTIVIRAL THERAPY, 20(7), 731-741.
WoS15 Europe PMC102015 Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., . . . Arribas, J. R. (2015). Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. LANCET HIV, 2(11), E464-E473.
WoS68 Europe PMC452015 Beyrer, C., Birx, D. L., Bekker, L. -G., Barre-Sinoussi, F., Cahn, P., Dybul, M. R., . . . Montaner, J. S. G. (2015). The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. LANCET, 386(9993), 505-507.
WoS21 Europe PMC172014 Boyd, M. A. (2014). Universal access to HIV care including antiretrovirals. The Lancet Infectious Diseases, 14(7), 562.
2014 Raffi, F., Babiker, A. G., Richert, L., Molina, J. -M., George, E. C., Antinori, A., . . . Pozniak, A. (2014). Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. LANCET, 384(9958), 1942-1951.
WoS144 Europe PMC972014 Haskelberg, H., Pocock, N., Amin, J., Ebeling, P., Emery, S., & Carr, A. (2014). Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(4), e94858-1-e94858-8.
WoS4 Europe PMC32014 Haskelberg, H., Cordery, D., Amin, J., Kelleher, A., Cooper, D., & Emery, S. (2014). HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(3), e93333-1-e93333-7.
WoS4 Europe PMC32014 McManus, H., Petoumenos, K., Franic, T., Kelly, M., Watson, J., O’Connor, C., . . . Law, M. (2014). Determinants of suicide and accidental or violent death in the Australian HIV Observational Database. PLoS ONE, 9(2), e89089-1-e89089-8.
WoS18 Europe PMC132014 Wright, S., Hoy, J., Mulhall, B., O'connor, C., Petoumenos, K., Read, T., . . . Boyd, M. (2014). Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 66(1), 55-64.
Scopus20 WoS17 Europe PMC172014 Holt, S., Gracey, D., Levy, M., Mudge, D., Irish, A., Walker, R., . . . Boyd, M. (2014). A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 11(1), 35-1-35-10.
Scopus14 WoS13 Europe PMC82014 Revell, A., Boyd, M., Wang, D., Emery, S., Gazzard, B., Reiss, P., . . . Larder, B. (2014). A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 15(7), 442-448.
Scopus3 WoS3 Europe PMC12014 Haskelberg, H., Mallon, P. W. G., Hoy, J., Amin, J., Moore, C., Phanuphak, P., . . . Emery, S. (2014). Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. Journal of Acquired Immune Deficiency Syndromes, 67(2), 161-168.
Scopus15 WoS15 Europe PMC142014 Achhra, A., Boyd, M., Law, M., Matthews, G., Kelleher, A., & Cooper, D. (2014). Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial. PLoS ONE, 9(6), e99530.
Scopus3 WoS3 Europe PMC22014 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
Scopus131 WoS130 Europe PMC882013 Boyd, M. (2013). Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. The Lancet, 381(9883), 2091-2099.
Scopus137 WoS131 Europe PMC992013 Wright, S., Petoumenos, K., Boyd, M., Carr, A., Downing, S., O'Connor, C., . . . Law, M. (2013). Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Medicine, 14(4), 208-216.
Scopus19 WoS16 Europe PMC142013 Wright, S., Boyd, M., Yunihastuti, E., Law, M., Sirisanthana, T., Hoy, J., . . . Petoumenos, K. (2013). Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS ONE, 8(6), e64902-1-e64902-12.
Scopus13 WoS11 Europe PMC132013 Achhra, A. C., & Boyd, M. A. (2013). Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Research and Therapy, 10(1), 33.
Scopus26 WoS25 Europe PMC222013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Second-line study team. (2013). HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One, 8(10), e77138-1-e77138-9.
Scopus14 WoS13 Europe PMC102013 Boyd, M. A., & Cooper, D. A. (2013). SPRING-2 the future of antiretroviral therapy. The Lancet Infectious Diseases, 13(11), 908-909.
Scopus4 WoS4 Europe PMC32013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Boyd, M. (2013). Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS, 27(15), 2403-2411.
Scopus33 WoS31 Europe PMC232013 Boyd, M. A., & Donovan, B. (2013). Antiretroviral therapy: Dolutegravir sets SAIL(ING). The Lancet, 382(9893), 664-666.
Scopus5 WoS4 Europe PMC12013 Schneider, K., Nwizu, C., Kaplan, R., Anderson, J., Wilson, D., Emery, S., . . . Boyd, M. (2013). The potential cost and benefits of raltegravir in simplified second-line therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE, 8(2), e54435.
Scopus2 WoS2 Europe PMC22013 Byakwaga, H., Petoumenos, K., Ananworanich, J., Zhang, F., Boyd, M., Sirisanthana, T., . . . Emery, S. (2013). Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database. Journal of the International Association of Providers of AIDS Care, 12(4), 270-277.
Scopus3 Europe PMC22013 Jansson, J., Wilson, D., Carr, A., Petoumenos, K., & Boyd, M. (2013). Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS, 27(8), 1245-1251.
Scopus12 WoS12 Europe PMC122013 Petoumenos, K., van Leuwen, M., Vajdic, C., Woolley, I., Chuah, J., Templeton, D., . . . Law, M. (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Medicine, 14(2), 77-84.
WoS24 Europe PMC202013 Guy, R., Wand, H., McManus, H., Vonthanak, S., Woolley, I., Honda, M., . . . Carr, A. (2013). Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for 'Test and Treat' Prevention Strategy. AIDS PATIENT CARE AND STDS, 27(12), 681-691.
WoS21 Europe PMC172012 Boyd, M. A., & Cooper, D. A. (2012). Optimisation of HIV care and service delivery: Doing more with less. The Lancet, 380(9856), 1860-1866.
Scopus12 WoS12 Europe PMC92012 Carey, D., Pett, S., Bloch, M., Wand, H., MacRae, K., Beileiter, K., . . . Cooper, D. (2012). A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. Journal of Acquired Immune Deficiency Syndromes, 60(2), 143-149.
Scopus17 WoS15 Europe PMC112012 McManus, H., O'Connor, C., Boyd, M., Broom, J., Russell, D., Watson, K., . . . Law, M. (2012). Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE, 7(11), e48839.
Scopus61 WoS62 Europe PMC492012 Avihingsanon, A., Van Der Lugt, J., Singphore, U., Gorowara, M., Boyd, M., Ananworanich, J., . . . Ruxrungtham, K. (2012). Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study. AIDS Research and Human Retroviruses, 28(10), 1170-1176.
Scopus6 WoS5 Europe PMC32012 Boyd, M., & Mohapi, L. (2012). Stretching delivery of HIV health services. The Lancet, 380(9845), 865-867.
2012 Haskelberg, H., Hoy, J., Amin, J., Ebeling, P., Emery, S., Carr, A., . . . Woolley, I. (2012). Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 7(6), 1-9.
Scopus83 WoS82 Europe PMC592012 Boyd, M. (2012). Dolutegravir-a promising antiretroviral in development. The Lancet Infectious Diseases, 12(2), 90-91.
Scopus8 WoS8 Europe PMC42011 Revell, A., Wang, D., Boyd, M., Emery, S., Pozniak, A., De Wolf, F., . . . Larder, B. (2011). The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS, 25(15), 1855-1863.
Scopus24 WoS21 Europe PMC172011 Byakwaga, H., Kelly, M., Purcell, D., French, M., Amin, J., Lewin, S., . . . Emery, S. (2011). Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 <sup>+</sup> T-cell response: A randomized controlled trial. Journal of Infectious Diseases, 204(10), 1532-1540.
Scopus51 WoS48 Europe PMC402011 Martin, A., Amin, J., Emery, S., Baker, D., Carr, A., Cooper, D., & Bloch, M. (2011). Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 6(10), e26885.
WoS23 Europe PMC42011 Kowalska, J. D., Friis-Moller, N., Kirk, O., Bannister, W., Mocroft, A., Sabin, C., . . . Lundgren, J. D. (2011). The Coding Causes of Death in HIV (CoDe) Project Initial Results and Evaluation of Methodology. EPIDEMIOLOGY, 22(4), 516-523.
WoS118 Europe PMC912011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
WoS26 Europe PMC212011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
WoS26 Europe PMC212011 Wright, S. T., Carr, A., Woolley, I., Giles, M., Hoy, J., Cooper, D. A., & Law, M. G. (2011). CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(1), 72-79.
WoS10 Europe PMC82011 Wilson, D. P., Grulich, A. E., & Boyd, M. (2011). Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men. Clinical Infectious Diseases, 53(6), 611-612.
Scopus2 WoS2 Europe PMC12010 Zhou, J., Li, P. C. K., Kumarasamy, N., Boyd, M., Chen, Y. M. A., Sirisanthana, T., . . . Pujari, S. (2010). Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine, 11(1), 31-39.
Scopus25 WoS23 Europe PMC192010 Martin, A., Amin, J., Cooper, D. A., Carr, A., Kelleher, A. D., Bloch, M., . . . Emery, S. (2010). Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS, 24(17), 2657-2663.
WoS43 Europe PMC352010 Carey, D., Amin, J., Boyd, M., Petoumenos, K., & Emery, S. (2010). Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 65(9), 1878-1888.
Scopus37 WoS34 Europe PMC232010 Boyd, M. A., & Hill, A. M. (2010). Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. PharmacoEconomics, 28(SUPPL. 1), 17-34.
Scopus16 WoS12 Europe PMC62010 Boyd, M. A. (2010). Current and future management of treatment failure in low- and middle-income countries. Current Opinion in HIV and AIDS, 5(1), 83-89.
Scopus16 WoS14 Europe PMC132010 Boyd, M. A., & Nwizu, C. A. (2010). Operational research in HIV priority areas: the African way. The Lancet, 376(9734), 4-6.
Scopus2 WoS2 Europe PMC22009 Boyd, M., Emery, S., & Cooper, D. A. (2009). Antiretroviral roll-out: the problem of second-line therapy. The Lancet, 374(9685), 185-186.
Scopus18 WoS17 Europe PMC142009 Boyd, M. A. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194-199.
Scopus48 WoS43 Europe PMC422009 Byakwaga, H., Murray, J. M., Petoumenos, K., Kelleher, A. D., Law, M. G., Boyd, M. A., . . . Cooper, D. A. (2009). Evolution of CD4<sup>+</sup> T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Research and Human Retroviruses, 25(6), 569-576.
Scopus5 WoS7 Europe PMC72009 Byakwaga, H., Zhou, J., Petoumenos, K., Law, M. G., Boyd, M. A., Emery, S., . . . Mallon, P. W. (2009). Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. HIV Medicine, 10(3), 143-151.
Scopus3 WoS3 Europe PMC32009 Boyd, M. (2009). Clinical research in low- And middle-income countries. Virtual Mentor, 11(7), 511-515.
Scopus12008 Colebunders, R., French, M., Oelrichs, R., & Boyd, M. (2008). Editorial introductions. Current Opinion in HIV and AIDS, 3(4), vii-viii.
2008 Boyd, M., & Pett, S. (2008). HIV fusion inhibitors: A review. Australian Prescriber, 31(3), 66-69.
Scopus12008 Boyd, M., & Byakwaga, H. (2008). Considering the benefits of disease-specific interventions on overall public health. The Lancet Infectious Diseases, 8(5), 278.
Scopus1 WoS1 Europe PMC12008 Oelrichs, R., & Boyd, M. (2008). Evidence and policy in the globalized response to AIDS. Current Opinion in HIV and AIDS, 3(4), 477-480.
2008 Boyd, M. A., Truman, M., Hales, G., Anderson, J., Dwyer, D. E., & Carr, A. (2008). A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antiviral Therapy, 13(3), 449-453.
Scopus9 WoS8 Europe PMC52007 Boyd, M. A., & Cooper, D. A. (2007). Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research. AIDS, 21(SUPPL. 4), S55-S63.
Scopus34 WoS30 Europe PMC282007 Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M. A., Phanuphak, P., Cooper, D. A., & Law, M. G. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54.
Scopus14 WoS11 Europe PMC112007 Boyd, M. A., Menon, P., Graves, S., & Gordon, D. L. (2007). A febrile illness with generalized papular rash involving the palms and soles. Clinical Infectious Diseases, 44(5), 704-756.
Scopus12007 Snelling, T., Ossowicz, C., & Boyd, M. (2007). Case report: Co-infections in an HIV-infected man from Malawi. American Journal of Tropical Medicine and Hygiene, 76(1), 180-181.
2007 Autar, R. S., Boyd, M. A., Wit, F. W. M. N., Ruxrungtham, K., Sankote, J., Lange, J. M. A., . . . Reiss, P. (2007). Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antiviral Therapy, 12(8), 1265-1271.
Scopus5 WoS7 Europe PMC52007 Cooper, D., Cahn, P., Lewin, S., Kaldor, J., McClure, C., Kort, R., & Boyd, M. (2007). The Sydney Declaration: a call to scale up research. Lancet, 370(9581), 7-8.
Scopus14 Europe PMC102007 Boyd, M. (2007). Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?. Expert Opinion on Pharmacotherapy, 8(7), 957-964.
Scopus16 WoS15 Europe PMC92007 Kerr, S. J., Duncombe, C., Avihingsanon, A., Ananworanich, J., Boyd, M., Sopa, B., . . . Ruxrungtham, K. (2007). Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. Journal of the International Association of Physicians in AIDS Care, 6(1), 36-46.
Scopus10 Europe PMC72007 Boyd, M. A., & Hedger, S. (2007). An unusual cause of severe metabolic acidosis [5]. Medical Journal of Australia, 186(3), 158.
2006 Boyd, M., & Reiss, P. (2006). The long-term consequences of antiretroviral therapy: A review. Journal of HIV Therapy, 11(2), 26-35.
Scopus17 Europe PMC132006 Boyd, M., Clezy, K., Lindley, R., & Pearce, R. (2006). Pandemic influenza: Clinical issues. Medical Journal of Australia, 185(10 SUPPL.), S44-S47.
Scopus33 WoS29 Europe PMC182006 Boyd, M., & Reiss, P. (2006). Erratum: The long-term effects of antiretroviral therapy: A review (Journal of HIV Therapy 11, 2 (28)). Journal of HIV Therapy, 11(3). 2006 Boyd, M. A., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., . . . Reiss, P. (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Journal of Infectious Diseases, 194(5), 642-650.
Scopus27 WoS27 Europe PMC192006 Boyd, M. A., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P. I., Uchaipichat, V., Stek, M., . . . Miners, J. O. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics, 16(5), 321-329.
Scopus56 WoS45 Europe PMC322006 Boyd, M. A., Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A., Lange, J. M. A., . . . Burger, D. M. (2006). The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. Journal of Antimicrobial Chemotherapy, 57(6), 1161-1167.
Scopus21 WoS19 Europe PMC102006 Boyd, M. A., Dixit, N. M., Siangphoe, U., Buss, N. E., Salgo, M. P., Lange, J. M. A., . . . Ruxrungtham, K. (2006). Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). Journal of Infectious Diseases, 194(9), 1319-1322.
Scopus11 WoS9 Europe PMC62006 Boyd, M. A., Burger, D. M., Phanuphak, P., & Cooper, D. A. (2006). Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]. AIDS, 20(7), 1083-1085.
Scopus3 WoS2 Europe PMC22006 Boyd, M. A., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E. A. M., Duncombe, C. J., . . . Phanuphak, P. (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232.
Scopus17 WoS14 Europe PMC102006 Kong, A., Koukourou, A., Boyd, M., & Crowe, G. (2006). Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. Journal of Clinical Neuroscience, 13(9), 955-958.
Scopus16 WoS9 Europe PMC92006 Boyd, M., & Rogers, W. (2006). Industry and bioethics: What price the relationship? [3]. PLoS Medicine, 3(6), 0933.
Scopus1 WoS1 Europe PMC12005 Boyd, M. A., Siangphoe, U., Ruxrungtham, K., Duncombe, C. J., Stek, M., Lange, J. M. A., . . . Phanuphak, P. (2005). Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Medicine, 6(6), 410-420.
Scopus15 WoS11 Europe PMC82005 Boyd, M., Mootsikapun, P., Burger, D., Chuenyam, T., Ubolyam, S., Mahanontharit, A., . . . Ruxrungtham, K. (2005). Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral Therapy, 10(2), 301-307.
Scopus40 WoS37 Europe PMC282004 Ananworanich, J., Cheunyam, T., Teeratakulpisarn, S., Boyd, M. A., Ruxrungtham, K., Lange, P. J., . . . Phanuphak, P. P. (2004). Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet, 364(9428), 101-102.
Scopus19 WoS18 Europe PMC102004 Law, W. P., Duncombe, C. J., Mahanontharit, A., Boyd, M. A., Ruxrungtham, K., Lange, J. M. A., . . . Dore, G. J. (2004). Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS, 18(8), 1169-1177.
Scopus137 WoS123 Europe PMC982004 Ruxrungtham, K., Boyd, M., Bellibas, S. E., Zhang, X., Dorr, A., Kolis, S., . . . Patel, I. H. (2004). Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology, 44(7), 793-802.
Scopus25 WoS20 Europe PMC162003 Law, W. P., Dore, G. J., Duncombe, C. J., Mahanontharit, A., Boyd, M. A., Ruxrungtham, K., . . . Cooper, D. A. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
WoS89 Europe PMC642003 Law, W. P., Dore, G. J., Duncombe, C. J., Mahanontharit, A., Boyd, M. A., Ruxrungtham, K., . . . Cooper, D. A. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
Scopus1062003 Boyd, M. A., Zhang, X., Dorr, A., Ruxrungtham, K., Kolis, S., Nieforth, K., . . . Patel, I. H. (2003). Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. Journal of Clinical Pharmacology, 43(12), 1382-1391.
Scopus43 WoS37 Europe PMC262003 Boyd, M. A., Aarnoutse, R. E., Ruxrungtham, K., Stek, M., Van Heeswijk, R. P. G., Lange, J. M. A., . . . Burger, D. M. (2003). Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes, 34(2), 134-139.
Scopus19 WoS19 Europe PMC142003 Burger, D., Boyd, M., Duncombe, C., Felderhof, M., Mahanontharit, A., Ruxrungtham, K., . . . Reiss, P. (2003). Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy, 51(5), 1231-1238.
Scopus59 WoS52 Europe PMC35 -
Book Chapters
Year Citation 2018 Boyd, M., & Crowe, S. (2018). Indinavir. In M. L. Grayson, S. E. Cosgrove, S. Crowe, W. Hope, J. S. McCarthy, J. Mills, . . . D. L. Paterson (Eds.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 4061-4074). Boca Raton, FL; USA: CRC Press.
2010 Boyd, M., & Cooper, D. A. (2010). Antiretroviral agents. In Antibiotic and Chemotherapy: Expert Consult (pp. 427-451). Elsevier.
2010 Boyd, M. A., & Cooper, D. A. (2010). Antiretroviral Therapy. In R. G. Finch, D. Greenwood, S. R. Norrby, & R. J. Whitley (Eds.), Antibiotic and Chemotherapy (9 ed., pp. 427-451). Elsevier Health Sciences. -
Conference Papers
Year Citation 2022 Van, L., Boyd, M. A., Neadley, K. E., & Hocking, C. (2022). Oncology social determinants of health. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 173). WILEY. 2021 Lau, A., Kong, F. Y. S., Fairley, C. K., Templeton, D. J., Amin, J., Phillips, S., . . . Hocking, J. S. (2021). TREATMENT EFFICACY OF 1G AZITHROMYCIN VERSUS 100MG DOXYCYCLINE BI-DAILY FOR SEVEN DAYS FOR ASYMPTOMATIC RECTAL CHLAMYDIA TRACHOMATIS. In SEXUAL HEALTH Vol. 18 (pp. XX). CSIRO PUBLISHING. -
Conference Items
Year Citation 2016 Boyd, M. A. (2016). HIV in Myanmar.. Poster session presented at the meeting of 2016 International Congress for Tropical Medicine and Malaria. Brisbane, Queensland, Australia. 2014 Holt, S. G., Gracey, D. M., Mudge, D. W., Irish, A. B., Sevastos, J., Walker, R. G., . . . Boyd, M. A. (2014). RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL.
Grants and Funding
Category 1
| 2014 - 2017 | Clinical Development Award clinical support for 4 years | NHMRC | $404,884 AUD |
| 2013 | Project Grant award support of the SECOND-LINE study | NHMRC | $449,584 AUD |
Category 2
| 2014 | Australian Award Fellowship support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) | Australian Commonwealth Government Department of Foreign Affairs & Trade. | $656,888 |
| 2013 | Australian Award Fellowships support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) | AusAID | $698,160 |
Category 3
| 2015 | In support of the development of capacity to measure ARV levels in human tissues: | Merck & Co. IISP grant | $20,000 AUD |
| 2015 | Award in support of Faster and smarter identification of at-risk sexually transmitted infection patients via online, mobile and social platforms | auDA foundation | $20,000 AUD |
| 2014 | Award in project support of The association between virological failure and lopinavir plasma drug levels in the SECOND-LINE trial | Gilead Australia Fellowship Research Grants | 2015: $30,000 AUD |
| 2014 | Independent initiative grant support for an analysis of bone turnover, immune activation and inflammatory biomarkers in the SECOND-LINE DXA-substudy, | Grants Merck Global Affairs | 2014: $304,064 AUD |
| 2012 | Award for support of the RATE study | Gilead Australia Fellowship Research Grants | 2013: $20,000 AUD |
| 2012 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2012: $125,000 USD |
| 2012 | Support of the SECOND-LINE study | Merck & Co. | $1,000,000 USD. |
| 2011 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2011: $125,000 USD |
| 2010 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2010: $125,000 USD |
| 2009 | Support of the SECOND-LINE study | Abbott Inc. | $600,000 AUD |
| 2009 | Support of the SECOND-LINE study | Merck & Co. | 2009: $1,100,000 USD |
| 2008 | Support of the Encore program | Bill and Melinda Gates Foundation | $12,416,901 USD |
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Principal Supervisor Use of a Next Generation Precision Health Platform to support Atrial Fibrillation Management Doctor of Philosophy Doctorate Full Time Miss Anh Hong Nguyen 2022 Principal Supervisor To determine asymptomatic cognitive decline in atrial fibrillation patients and to investigate their mechanistic links Doctor of Philosophy Doctorate Full Time Mr Rakesh Agarwal 2022 Principal Supervisor Perioperative Haemostasis and Anticoagulation Master of Philosophy (Clinical Science) Master Part Time Mr Brandon John Lee Stretton 2022 Principal Supervisor Integrating social and medical care at a hospital serving a disadvantaged urban community in South Australia Doctor of Philosophy Doctorate Full Time Miss Kate Emily Neadley -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2021 - 2023 Principal Supervisor The Use of Objective Data to Access Activity and Participation Prior to and Following Critical Illness: Feasibility of Smartphone Data-Capture Doctor of Philosophy Doctorate Part Time Dr Samuel Gluck 2020 - 2023 Principal Supervisor CHARACTERISATION OF THE RELATIONSHIP BETWEEN RADIOFREQUENCY CATHETER ABLATION PARAMETERS AND ATRIAL FIBRILLATION ABLATION LESION FORMATION Doctor of Philosophy Doctorate Full Time Ms Tira Rattanakosit -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2015 - 2020 Co-Supervisor Biomarkers of Metabolic Outcomes of Second-Line Antiretroviral Therapy Regimens in Low and Middle-Income Countries University of New South Wales Doctor of Philosophy Doctorate Part Time Gwamaka Mwasakifwa
-
Board Memberships
Date Role Board name Institution name Country 2020 - 2019 Co-Chair Asia Pacific AIDS & Coinfections Conference Virology Education Thailand 2015 - ongoing Member Scientific and Program Committee of the Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Conference 2016 Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Australia -
Committee Memberships
Date Role Committee Institution Country 2015 - ongoing Chair ASHM International Advisory Group - - 2014 - ongoing Member Australian National HIV Pre-Exposure Prophylaxis (PrEP) Guidance Committee - - 2014 - ongoing Chair RACP Working Group - - 2014 - ongoing President Australasian Society for HIV Medicine (ASHM) - - 2014 - ongoing Chair Gilead ‘HIV and the Body’ educational meeting faculty - - 2013 - ongoing Chair Lyell McEwin Hospital, Discipline of Medicine, School of Medicine University of Adelaide - 2013 - ongoing Member NEAT-id (European Treatment Network for HIV, Hepatitis and Global Infectious Diseases) - - 2013 - ongoing Member Australasian Society for HIV Medicine (ASHM) Clinical Guidance Committee - - 2013 - ongoing Chair National Program Theme B Committee for the ASHM 2013 National Conference - - 2012 - ongoing Member Kirby Institute Higher Degree Committee and Annual Post-Graduate Progress Review academic staff - - 2012 - ongoing Member ASID Prosthetic Joint Infection Trial Steering Committee - - 2012 - ongoing Member ASHM NSW HIV Shared Care Workshop Committee - - 2012 - ongoing Member Australian Society for Infectious Disease (ASID) Native Joint Infection Trial Steering Committee - - 2011 - 2014 Vice-President Australasian Society for HIV Medicine (ASHM) - - 2010 - ongoing Member Australian HIV Observational Database (AHOD) Steering Committee - - 2009 - ongoing Vice-President Australasian Society for HIV Medicine - - 2009 - ongoing Member ASHM Risk Management and Audit Sub-Committee - - 2005 - 2009 Board Member Australasian Society for HIV Medicine - - 2005 - ongoing Board Member Australasian Society for HIV Medicine (ASHM) - - 1999 - 2005 Member Australasian Society for HIV Medicine - - -
Consulting/Advisories
Date Institution Department Organisation Type Country 2014 - ongoing International Advisory Board, Lancet HIV - - - 2014 - ongoing Merck Australian HIV Advisory Board - - - 2013 - ongoing ASHM NSW Expert Advisory Committee - - - 2013 - ongoing Gilead Sciences International HIV Advisory Board - - - -
Editorial Boards
Date Role Editorial Board Name Institution Country 2015 - ongoing Editor-In-chief AIDS Research & Therapy BMC open access journal - - -
Industry Partnerships
Date Engagement Type Partner Name 2014 - 2016 Consultant Honorary Consultant in HIV Medicine, The Albion Centre 2013 - ongoing Consultant HIV and Infectious Diseases Specialist Consultant, Holdsworth House Medical Practice
Connect With Me
External Profiles
